A Phase 3 trial of semaglutide (a GLP‐1 receptor agonist) also showed significant histological improvements, with 62.9% of patients achieving NASH resolution (corresponding to MASH resolution) and a notable fibrosis improvement rate [11]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.